Neurotoxicity associated with deferoxamine therapy
- 31 May 1988
- journal article
- Published by Elsevier in Toxicology
- Vol. 49 (2-3) , 283-290
- https://doi.org/10.1016/0300-483x(88)90010-8
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Subclinical VEP abnormalities in patients on chronic deferoxamine therapy: longitudinal studiesElectroencephalography and Clinical Neurophysiology/Evoked Potentials Section, 1987
- Visual and Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine InfusionsNew England Journal of Medicine, 1986
- Treatment of rheumatoid arthritis with desferrioxamine: relation between stores of iron before treatment and side effects.BMJ, 1985
- Prevention of Cardiac Disease by Subcutaneous Deferoxamine in Patients with Thalassemia MajorNew England Journal of Medicine, 1985
- OCULAR TOXICITY OF DESFERRIOXAMINEThe Lancet, 1985
- Depletion of excessive liver iron stores with desferrioxamineBritish Journal of Haematology, 1984
- VISUAL LOSS IN PATIENT ON HIGH-DOSE SUBCUTANEOUS DESFERRIOXAMINEThe Lancet, 1984
- DESFERRIOXAMINE, OCULAR TOXICITY, AND TRACE METALSThe Lancet, 1983
- OCULAR TOXICITY OF HIGH-DOSE INTRAVENOUS DESFERRIOXAMINEThe Lancet, 1983
- Response to long-term deferoxamine therapy in thalassemiaThe Journal of Pediatrics, 1981